Real-World Data Show Trastuzumab Deruxtecan Extends Survival in HER2-Low Metastatic Breast Cancer
A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...
A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.